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Introduction
The past 2 years have been marked by the discovery of 
some  30  new  genes  associated  with  type  2  diabetes 
mellitus (T2DM) and 40 associated with type 1 diabetes 
mellitus  (T1DM)  [1,2].  These  have  been  discovered  by 
association studies using very large sample sizes, and the 
susceptibility  alleles  discovered  are  associated  with 
modest increases in diabetes risk of 10 to 20%. Expression 
of these risk alleles is probably influenced by the presence 
of  other  diabetes  risk  factors,  such  as  lifestyle,  viral 
exposures and perhaps other genetic variants.
In  addition  to  the  susceptibility  genes  identified 
through conventional association studies, a small number 
of diabetes-associated genes has been discovered whose 
effects are mediated through imprinting. Imprinting is a 
type of genetic effect characterized by parent-to-offspring 
transmission whereby the expression of the phenotype in 
the  offspring  depends  on  whether  the  transmission 
originated from the mother or father. In imprinting, one 
allele of a specific gene is silenced (through epigenetic 
mechanisms such as methylation) when inherited from 
one parent but expressed when inherited from the other. 
Thus,  phenotype  expression  of  imprinted  genes  is  a 
consequence not only of sequence variation per se, but 
also of methylation and histone modifications that silence 
one allele, allowing a normal state of monoallelic gene 
expression without altering DNA sequence. The conse-
quence  of  the  imprinting  phenomenon  for  association 
studies is that sequence variation in only the expressed 
allele will influence phenotype, manifesting in a seem-
ingly  non-classical  transmission  or  inheritance  pattern 
that  may  obscure  any  genotype-phenotype  association. 
Variants that disrupt normal imprinting may also influ-
ence the nature of observed associations. Thus, account-
ing for the parent of origin of each allele at an imprinted 
locus should enhance the ability to identify susceptibility 
variants.
Imprinted  genes  are  in  fact  only  one  mechanism 
through which transmission of disease risk from parent 
to offspring may be influenced by the sex of the parent 
transmitting the susceptibility factor. Other mechanisms 
underlying parent-of-origin effects include mitochondrial 
transmission  and  maternal  effects  attributable  to  the 
intrauterine environment [3]. Mitochondrial transmission, 
for example, is a specific type of parent-of-origin effect 
resulting from the fact that mitochondria, and therefore 
sequence  variation  therein,  are  transmitted  from  the 
mother  but  not  the  father  to  the  offspring.  Although 
relatively  rare,  clear  examples  of  maternally  inherited 
diabetes  attributable  to  deletions  or  mutations  in  the 
mitochondrial genome have been documented [4-6], are 
often accompanied by deafness, and may account for as 
much  as  1%  of  the  overall  diabetes  burden  [7].  Mito-
chondrial transmission is different from disease suscep-
tibility  genes  that  are  transmitted  on  autosomes  but 
which  are  expressed  in  the  offspring  in  a  sex-specific 
manner.  Examples  of  autosomally  transmitted  alleles 
whose expression is modified by sex of the offspring are 
the BRCA1 and BRCA2 risk alleles associated with breast 
(and  other  forms  of)  cancer.  Although  risk  of  breast 
cancer is significantly enhanced in both male and female 
offspring who inherit BRCA1 and BRCA2 risk alleles, the 
actual risk will be much higher in female offspring. In 
contrast  to  imprinting,  however,  disease  risk  in  this 
example  is  influenced  by  the  sex  of  the  offspring  as 
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allele. A third class of parent-of-origin effect relates to 
maternal effects attributable to the intrauterine environ-
ment. Fetuses exposed to hyperglycemia (which can be 
influenced by maternal genes) or undernourish  ment in 
utero are at increased risk of a large spectrum of growth 
abnormalities,  including  developing  diabetes  in  the 
future  [8].  Although  such  effects  could  potentially  be 
mediated by methylation and histone modification of the 
maternal  or  fetal  genome,  the  phenomenon  need  not 
depend on mother-to-offspring transmission of specific 
disease-associated alleles.
The  role  of  imprinted  genes  in  human  disease  is 
incompletely  understood,  in  part  because  disease-
associated  imprinted  genes  are  difficult  to  detect  by 
conventional  association  methods  because  their  effects 
are  dependent  on  which  parent  transmitted  the  risk 
allele. Notwithstanding these difficulties, recognition of 
the genetic mechanisms underlying imprinting may have 
direct relevance to the diagnosis and clinical treatment of 
the disease (see below). Several comprehensive reviews 
on  imprinting  in  diseases  related  to  growth  and 
development have recently been published [9-11]. Here, 
we  provide  an  overview  of  imprinting  as  it  applies  to 
diabetes.
The biological basis of genetic imprinting
In diploid organisms, such as humans, all somatic cells 
have two copies of the genome, one copy inherited from 
each parent. For the vast majority of autosomal genes, 
both  alleles  at  each  locus  influence  expression  of  the 
gene. However, a small number of genes are imprinted, 
meaning that gene expression results from only a single 
allele  because  the  allele  transmitted  from  either  the 
mother or the father is silenced. It is believed that up to 
1% of human genes may be imprinted, and more than 150 
imprinted human genes have been identified so far, most 
of which are related to growth and development [12,13]. 
Imprinted  genes  can  have  a  significant  role  in  disease 
because  imposition  of  a  functional  haploid  state  at 
imprinted  loci  allows  a  single  mutation  event  to  be 
unopposed,  giving  it  greater  potential  to  affect  gene 
function.
Genomic  imprinting  is  related  to  the  methylation  of 
cytosine  bases  that  occurs  primarily  in  CpG  clusters. 
Such  regions  are  frequently  involved  in  regulation  of 
genes [14]. When DNA is methylated, a hydrogen atom 
of the cytosine base is replaced with a methyl group [15]. 
When  the  methylated  region  encompasses  a  gene,  the 
methylated allele is typically not transcribed and thus the 
methylation leads to gene silencing. Although high levels 
of  methylation  (hypermethylation)  are  generally  asso-
ciated with gene silencing, low levels of DNA methylation 
(hypomethylation)  are  generally  associated  with  higher 
gene activity [14]. Certain genomic regions are charac  ter-
istically  maternally  methylated  and  others  paternally 
methylated, and these are often in close proximity to one 
another.  Typically,  if  the  maternal  allele  is  methylated, 
only  the  paternal  allele  is  transcribed.  The  imprint  is 
normally reset in the germline such that, for example, a 
female’s  paternal  allele  will  take  on  a  maternal  methy-
lation pattern when passed on to her offspring. Abnormal 
phenotypes  due  to  incorrect  dosage  can  result  if  this 
resetting  process  fails  and  imprinted  alleles  retain  the 
original methylation profile of the parent from whom the 
allele  was  transmitted  [16].  Although  methylation  is 
typically  regarded  as  a  silencing  mechanism,  there  are 
cases  in  which  methylation  can  also  enhance  gene 
expression. For example, methylation of the paternal copy 
of a region on chromosome 11p15 between the imprinted 
genes IGF2 (encoding insulin-like growth factor 2) and 
H19  (an  RNA  gene)  prevents  a  factor  known  as  an 
‘insulator’  from  binding  to  the  region  and  allows 
enhancers to access and promote expression of IGF2 on 
the paternal chromosome [17]. In addition to methylation 
of  DNA,  imprinting  may  also  modify  gene  expression 
through  post-translational  modification  of  histones  or 
activation of microRNAs [18,19]. In addition, imprinting 
is  in  some  cases  tissue-specific  and/or  developmental-
period-specific  [17].  For  example,  the  imprinted  gene 
PLAGL1 (Pleomorphic adenoma gene-like 1, also known 
as ZAC), which is involved in transient neonatal diabetes 
(see below), is imprinted in fibroblasts but not lympho-
cytes [20].
The molecular modifications associated with methyla-
tion are termed ‘epigenetic’ because they involve changes 
to  DNA  structure  rather  than  changes  to  the  DNA 
sequence. The molecular modifications of DNA associated 
with genomic imprinting occur in germline cells and, like 
sequence  changes,  these  modifications  can  be  stably 
transmitted  through  several  generations  of  cells  or 
organisms.  However,  unlike  sequence  changes,  these 
epigenetic  modifications  can  also  be  reset,  or  undone, 
under appropriate conditions such as during primordial 
germ  cell  development  [21].  The  capability  to  reset 
methylation changes is thought to provide flexibility of 
the body to regulate the timing of gene expression during 
critical periods of growth and development, and in this 
light it is not surprising that imprinted genes tend to be 
found in evolutionarily conserved imprinted domains [21].
Besides  genomic  imprinting,  epigenetic  modification 
can  also  occur  in  response  to  environmental  stimuli 
[22,23],  such  as  parental  nutritional  status,  cigarette 
smoking,  toxins,  microbes,  endocrine  disruptors, 
chemicals and stress [24]. Although some of these other 
mechanisms may be transmitted at the organismal level 
and may also have a role in diabetes, less is known about 
them.
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far in humans affect growth and development [21,25,26]. 
Among the more well known imprinted human disorders 
are:  Prader-Willi  and  Angelman  syndromes,  involving 
deletions  and/or  inactivations  or  uniparental  disomy 
(two chromosomal homologs inherited from one parent) 
of chromosome 15q11-q13; Beckwith-Wiedemann syn-
drome,  involving  methylation  of  genes  in  the  11p15.5 
region;  Russell-Silver  syndrome,  involving  imprinted 
disturbances of chromosomes 7 or 11; and Albright here-
ditary osteodystrophy, due to mutations in an imprinted 
gene  on  chromosome  20q13.11.  Reviews  of  these 
disorders  have  recently  been  published  (for  example, 
[9,27]). In recent years, the involvement of imprinting in 
a sizeable proportion of cases of a rare form of diabetes, 
neonatal diabetes, has come to be appreciated.
6q24-related transient neonatal diabetes mellitus
Neonatal diabetes is a rare condition affecting approxi-
mately 1 in 100,000 to 1 in 500,000 newborns, with about 
half  being  affected  permanently  and  half  transiently 
[28-30]. Approximately 70% of transient neonatal diabetes 
mellitus (TNDM) results from abnormalities of a region 
on  chromosome  6q24  containing  the  imprinted  genes 
PLAGL1 and HYMAI (the RNA gene ‘Hydatidiform mole 
associated and imprinted’) [31]. 6q24-related TNDM is 
characterized  by  growth  retardation  and  by  diabetes 
developing during the first week of life and lasting, on 
average, 3 months but in some cases as long as 18 months. 
There  is  an  elevated  risk  of  diabetes  or  hyper  glycemic 
episodes  occurring  later  in  life.  Other  features  can 
include macroglossia (large tongue) and umbilical hernia.
The role of imprinting in 6q24-related TNDM
Approximately 40% of 6q24-related TNDM cases result 
from paternal uniparental disomy (UPD; inheritance of 
two paternal copies rather than one maternal and one 
paternal copy), usually isodisomy (two identical homo-
logs)  of  chromosome  6,  40%  from  (usually  submicro-
scopic) duplication of the 6q24 region on the paternally 
inherited chromosome 6 and 20% from hypomethylation 
of  the  maternal  PLAGL1-HYMAI  differentially  methy-
lated  region  (DMR).  As  these  two  genes  are  normally 
silenced  by  methylation  on  the  maternal  homolog  and 
expressed  on  the  paternal  homolog  during  the  fetal 
period, each of these three mechanisms results in twice 
the normal dosage of these two genes. The mechanism 
whereby  increased  dosage  at  the  6q24  region  leads  to 
hyperglycemia is not well understood, but PLAGL1 has 
been shown to be involved in apoptosis [20], regulation 
of insulin secretion [32] and fetal growth [33].
Hypomethylation  of  the  maternal  homolog  can  be 
caused either by an imprinting mutation in the region 
containing the maternal PLAGL1 promoter or as part of a 
generalized  ‘hypomethylation  at  imprinted  loci’  (HIL), 
the  latter  at  least  some  of  the  time  inherited  in  an 
autosomal recessive manner. More than 50% of cases of 
HIL  seem  to  result  from  recessive  mutations  in  the 
ZFP57  gene,  which  encodes  a  zinc  finger  protein.  The 
ZFP57  gene  is  also  on  chromosome  6  but  at  6p22, 
essentially  unlinked  to  the  PLAGL1-HYMAI  region. 
Among  the  nine  individuals  in  the  seven  pedigrees  in 
which  ZFP57  mutations  were  first  described  [34],  all 
showed, in addition to hypomethylation at the maternal 
6q24  DMR,  hypomethylation  at  PEG3  (paternally 
expressed  gene,  19q13)  and  GRB10  (growth  factor 
receptor-bound  protein  10,  7p11-12)  DMRs.  Some 
individuals also had hypomethylation of DMRs at PEG1 
(17q32), KCNQ1OT1 (an antisense transcript overlapping 
the potassium-channel-encoding gene KCNQ1 on 11p15), 
or NESPAS (an antisense transcript to the Novel erythro-
poiesis stimulating protein gene NESP on 20q13) [34]. As 
discussed  below,  single  nucleotide  polymorphisms 
(SNPs) at two of these loci (7q32 and 11p15) have been 
implicated in parent-of-origin-specific associations with 
T2DM  [35].  Association  of  SNPs  within  GRB10  with 
T2DM have also been reported [36,37], although results 
have been conflicting [38], perhaps in part as a result of 
lack of examination of parent-of-origin effects.
Clinical and genetic implications of a diagnosis of 
6q24-related TNDM
A  clinical  diagnosis  of  TNDM  is  suspected  in  infants 
with severe intrauterine growth retardation, dehydration, 
hyperglycemia, and hypoinsulinemia without ketoacidosis. 
The  diabetes  associated  with  overexpression  at  6q24 
usually resolves by 1 year of age, but children with this 
genetic subtype are at risk for intermittent hyperglycemic 
episodes and for developing T2DM, especially at puberty. 
Affected women may present with gestational diabetes. 
Children with HIL are at risk for developmental delay.
When  6q24-related  TNDM  is  suspected,  a  tiered 
genetic testing approach as summarized in Figure 1 has 
been  suggested  by  Temple  and  Mackay  [39],  who  are 
responsible for much of the research leading to current 
knowledge  about  6q24-related  TNDM.  This  approach 
can provide information used to assess risks of TNDM to 
other family members (Table 1).
Evidence for a role of imprinting in polygenic 
diabetes
Because specific imprinted genes have been associated 
with syndromes marked by extreme obesity (for example, 
Prader-Willi)  and  diabetes  (for  example,  TNDM),  it 
seems  likely  that  there  are  numerous  other  imprinted 
genes  having  milder  effects  on  obesity  and  diabetes. 
Epigenetic  regulation  and  imprinting  have  been  exten-
sively studied in mice [40], although there are substantial 
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imprinted genes in mice and humans [41], limiting the 
utility  of  the  mouse  model  to  understand  the  role  of 
genomic imprinting in humans. Alternative approaches 
for  identifying  new  imprinted  genes  in  humans  have 
included analysis of large family and population samples 
using both linkage approaches (for example, [42-46]) and 
association  approaches  (for  example,  [47-49])  that 
incorporate parent-of-origin effects.
T1DM
In a genome-wide association study of T1DM, the most 
strongly associated SNP (rs941576) was found in a well 
established  imprinted  region  on  chromosome  14q32.2 
[49]. Additional analyses incorporating parent-of-origin 
effects  were  then  undertaken  that  revealed  strong 
evidence  for  reduced  paternal  transmission  of  the 
protective  G  allele  at  this  locus.  On  the  basis  of  this 
result, the authors [49] suggested that the causal variant 
may alter expression of the paternal inherited copy of a 
nearby gene (possibly DLK1, which encodes Delta-like 1 
homolog).
T2DM
Variants in two imprinted genomic regions (at 11p15 and 
7q32)  were  identified  in  a  recent  study  carried  out  in 
Icelanders of SNPs in imprinted regions known as being 
associated with T2DM [35]. None of the variants were 
impressively associated with T2DM in the standard case-
control analysis, but in analysis incorporating parent-of-
origin  effects,  there  was  statistically  compelling  and 
independently  replicated  evidence  for  association  with 
the maternal allele but not the paternal allele at two SNPs 
at 11p15 and one SNP at 7q32. In addition, the paternal C 
allele at a fourth SNP, rs2334499 on chromosome 11p15, 
was  strongly  associated  with  increased  risk  for  T2DM 
when paternally inherited (OR = 1.41, P = 4 × 10-9) but 
moderately  associated  with  decreased  risk  for  T2DM 
when  maternally  inherited  (OR  =  0.87,  P  =  0.02).  In 
addition to the association with diabetes, the authors [35] 
Figure 1. Summary of tiered genetic testing approach for 
6q24-related transient neonatal diabetes mellitus (TNDM) 
as suggested by Temple and Mackay [39]. Adapted from 
and described in further detail in [39]; details of the method 
for determining the ratio of unmethylated to methylated DNA 
at 6q24 are in [34]. DMR, differentially methylated region; HIL, 
hypomethylation at imprinted loci; TNDM, transient neonatal 
diabetes mellitus; UPD, uniparental disomy. Paternal UPD is 
established after genotyping a panel of polymorphic markers on 
chromosome 6q in the parents and offspring and determining that 
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Table 1. Risk to other family members for each type of transient neonatal diabetes mellitus
Type of TNDM  Risk to other family members
Paternal UPD  Unlikely to recur in other family members 
Inherited paternal   The risk to siblings of inheriting the same duplication and being at risk for TNDM and later diabetes is 50%. Offspring of individuals 
duplication  with duplications are at 50% risk of inheriting the duplication, but at risk for TNDM or later diabetes if only the allele is inherited  
  from the father
Paternal chromosomal   Risks to family members depend on the particular rearrangement involved. For example, partial trisomy for 6q24 as a result of 
rearrangement  unbalanced inheritance of a paternal but not maternal balanced reciprocal translocation would include the TNDM phenotype
De novo duplication on   Some residual risk to siblings owing to the possibility of paternal gonadal or undetected somatic mosaicism for the duplication. 
the paternally inherited   Offspring of individuals with a de novo duplication have a 50% risk of inheriting the duplication, with offspring of males but not
chromosome  females at risk for TNDM or later diabetes
Imprinting mutation of   No familial recurrence has been reported. The causes of these mutations are not well understood and Temple and Mackay consider 
the 6q24 DMR   testing siblings of affected children for diabetes to be appropriate. The risk to offspring of females with imprinting center mutations  
  may theoretically be increased but no empirical data are available to support or refute this hypothesis
Generalized HIL  Over 50% have homozygosity or compound heterozygosity for ZFP57 mutations as determined by sequencing. There is a 25% 
  recurrence risk in siblings of a child who has inherited two ZFP57 mutations from carrier parents. The penetrance is not known. 
  The recurrence risk for other forms of HIL is not known because the cause(s) are not known
Adapted from and described in further detail in [39]. Abbreviations: HIL, hypomethylation at imprinted loci; TNDM, transient neonatal diabetes mellitus; UPD, 
uniparental disomy.
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correlated with reduced expression of nearby candidate 
gene  KLF14  (which  encodes  the  transcription  factor 
Krüppel-like factor 14) in adipose tissue (P = 3 × 10-21) 
only when inherited maternally.
Conclusions and clinical implications
In recent years, efforts to identify imprinted genes have 
been  enhanced  greatly  by  the  development  of  new 
genome-scale technologies for epigenomic profiling (for 
example,  [50])  and  by  the  cataloguing  of  known  im-
printed genes [12,51]. Indeed, epidemiological studies of 
diabetes and many other complex diseases have begun to 
consider  the  role  of  genetic  imprinting  and  more 
generally  how  epigenetic  modification  can  mediate 
environ  mental influences on gene expression [52].
As demonstrated by the case of 6q24-related TNDM, 
knowledge  of  the  role  of  imprinting  in  disease  has 
profound  implications  for  recurrence  risks  in  relatives. 
Using known SNPs to predict risk for polygenic T1DM or 
T2DM has not yet proven useful in a clinical setting. As 
the genetic architecture of these diseases continues to be 
revealed,  such  prediction  may  become  feasible,  and 
knowledge of the imprinting status of the relevant loci is 
likely to be an important component of building accurate 
risk models. Regardless of future clinical usage, paying 
careful  attention  to  imprinting  status  clearly  enhances 
the  ability  to  accurately  detect  associations  that  will 
ultimately provide information important for continuing 
to elucidate the etiology of these complex diseases.
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